Mesalamine Patent Expiration
Mesalamine was first introduced by Mylan Specialty Lp
Mesalamine Patents
Given below is the list of patents protecting Mesalamine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Apriso | US8865688 | Compositions and methods for treatment of bowel diseases with granulated mesalamine | May 01, 2030 | Salix |
| Canasa | US8217083 | Mesalamine suppository | Jun 06, 2028 | Abbvie |
| Canasa | US8436051 | Mesalamine suppository | Jun 06, 2028 | Abbvie |
| Sfrowasa | US7645801 | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) | Jul 24, 2027 | Mylan Speciality Lp |
| Asacol Hd | US6893662 | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
Nov 15, 2021
(Expired) | Abbvie |
| Asacol Hd | US8580302 | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
Nov 15, 2021
(Expired) | Abbvie |
| Asacol Hd | US9089492 | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
Nov 15, 2021
(Expired) | Abbvie |
| Lialda | US6773720 | Mesalazine controlled release oral pharmaceutical compositions |
Jun 08, 2020
(Expired) | Takeda Pharms Usa |
| Delzicol | US6649180 | Hard capsule formed of cellulose ether film with a specific content of methoxyl and hydroxypropoxyl groups |
Apr 13, 2020
(Expired) | Abbvie |
| Apriso | US6551620 | Pellet formulation for the treatment of the intestinal tract |
Apr 20, 2018
(Expired) | Salix |
| Apriso | US8337886 | Pellet formulation for the treatment of the intestinal tract |
Apr 20, 2018
(Expired) | Salix |
| Apriso | US8496965 | Pellet formulation for the treatment of the intenstinal tract |
Apr 20, 2018
(Expired) | Salix |
| Apriso | US8911778 | Pellet formulation for the treatment of the intestinal tract |
Apr 20, 2018
(Expired) | Salix |
| Apriso | US8940328 | Pellet formulation for the treatment of the intestinal tract |
Apr 20, 2018
(Expired) | Salix |
| Apriso | US8956647 | Pellet formulation for the treatment of the intestinal tract |
Apr 20, 2018
(Expired) | Salix |
| Asacol | US5541170 | Orally administrable pharmaceutical compositions |
Jul 30, 2013
(Expired) | Apil |
| Asacol | US5541171 | Orally administrable pharmaceutical composition |
Jul 30, 2013
(Expired) | Apil |
| Asacol Hd | US5541170 | Orally administrable pharmaceutical compositions |
Jul 30, 2013
(Expired) | Abbvie |
| Asacol Hd | US5541171 | Orally administrable pharmaceutical composition |
Jul 30, 2013
(Expired) | Abbvie |
| Delzicol | US5541170 | Orally administrable pharmaceutical compositions |
Jul 30, 2013
(Expired) | Abbvie |
| Delzicol | US5541171 | Orally administrable pharmaceutical composition |
Jul 30, 2013
(Expired) | Abbvie |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Mesalamine's patents.
Latest Legal Activities on Mesalamine's Patents
Given below is the list recent legal activities going on the following patents of Mesalamine.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 29 Jun, 2021 | US7645801 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 11 Jul, 2013 | US7645801 |
| Patent Issue Date Used in PTA Calculation Critical
| 12 Jan, 2010 | US7645801 |
| Recordation of Patent Grant Mailed Critical
| 12 Jan, 2010 | US7645801 |
| Issue Notification Mailed Critical
| 23 Dec, 2009 | US7645801 |
| Application Is Considered Ready for Issue Critical
| 11 Dec, 2009 | US7645801 |
| Dispatch to FDC | 11 Dec, 2009 | US7645801 |
| Issue Fee Payment Verified Critical
| 10 Dec, 2009 | US7645801 |
| Issue Fee Payment Received Critical
| 10 Dec, 2009 | US7645801 |
| Response to Reasons for Allowance | 07 Dec, 2009 | US7645801 |
Mesalamine's Family Patents
